middle.news
Paradigm Biopharma Upsizes Placement to A$14m, Boosts Funding to A$45m Ahead of Knee OA Trial Interim Analysis
10:43am on Monday 27th of April, 2026 AEST
•
Healthcare
Read Story
Paradigm Biopharma Upsizes Placement to A$14m, Boosts Funding to A$45m Ahead of Knee OA Trial Interim Analysis
10:43am on Monday 27th of April, 2026 AEST
Key Points
Phase 3 PARA_OA_012 trial surpasses 50% patient dosing milestone
A$14 million placement upsized from A$8 million due to strong demand
Share Purchase Plan launched to raise up to A$2 million
Pro forma cash position of approximately A$45 million post-raise
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE